公开(公告)号：US06358933B1

公开(公告)日：2002-03-19

申请号：US09530925

申请日：2000-05-05

申请人： Julio Cesar Aguilar Rubido ,  Verena Lucila Muzio Gonzalez ,  Gerardo Enrique Guillen Nieto ,  Eduardo Penton Arias ,  Maria de Jesus Leal Angulo ,  Dagmara Pichardo Diaz ,  Enrique Iglesias Perez ,  Antonieta Herrera Buch ,  Belquis Sandez Oquendo ,  Alexis Musacchio Lasa ,  Diogenes Quitana Vazquez ,  Lissere Crombet Menedez

发明人： Julio Cesar Aguilar Rubido ,  Verena Lucila Muzio Gonzalez ,  Gerardo Enrique Guillen Nieto ,  Eduardo Penton Arias ,  Maria de Jesus Leal Angulo ,  Dagmara Pichardo Diaz ,  Enrique Iglesias Perez ,  Antonieta Herrera Buch ,  Belquis Sandez Oquendo ,  Alexis Musacchio Lasa ,  Diogenes Quitana Vazquez ,  Lissere Crombet Menedez

IPC分类号： A61K3170

CPC分类号： A61K39/21 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/39 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55583 ,  C12N2740/16034

摘要： The present invention is for a formulation comprising a nucleic acid vaccine and an immunoenhancing amount of acemannan, whereby the acemannan enhances immune response, in a host, to the vaccine. The present invention is also for a method of enhancing the immune response of a host to a nucleic acid vaccine by administering a formulation comprising a nucleic acid vaccine and acemannan.

摘要翻译： 本发明涉及一种包含核酸疫苗和免疫增强量的acemannan的制剂，其中所述acemannan在宿主中增强疫苗的免疫应答。 本发明还涉及一种通过施用包含核酸疫苗和acemannan的制剂来增强宿主对核酸疫苗的免疫应答的方法。

公开(公告)号：US06355414B1

公开(公告)日：2002-03-12

申请号：US09380790

申请日：2000-01-06

申请人： Julio Cesar Aguilar Rubido ,  Verena Lucila Muzio Gonzalez ,  Maria de Jesus Leal Angulo ,  Gerardo Enrique Guillen Nieto ,  Eduardo Penton Arias ,  Gloria Veliz Rios ,  Dagmara Pichardo Diaz ,  Antonieta Herrera Buch ,  Enrique Iglesias Perez ,  Luis Javier Cruz Ricondo ,  Tania Carmenate Portilla ,  Cirse Mesa Pardillo ,  Maydel Hechavarria Gay ,  Maylin Diaz Martinez ,  Juan Joel Madrazo Piñol

发明人： Julio Cesar Aguilar Rubido ,  Verena Lucila Muzio Gonzalez ,  Maria de Jesus Leal Angulo ,  Gerardo Enrique Guillen Nieto ,  Eduardo Penton Arias ,  Gloria Veliz Rios ,  Dagmara Pichardo Diaz ,  Antonieta Herrera Buch ,  Enrique Iglesias Perez ,  Luis Javier Cruz Ricondo ,  Tania Carmenate Portilla ,  Cirse Mesa Pardillo ,  Maydel Hechavarria Gay ,  Maylin Diaz Martinez ,  Juan Joel Madrazo Piñol

IPC分类号： C12Q170

CPC分类号： A61K39/095 ,  A61K39/12 ,  A61K39/292 ,  A61K2039/54 ,  A61K2039/543 ,  A61K2039/55544 ,  A61K2039/55583 ,  A61K2039/55588 ,  C12N2730/10134 ,  Y10S514/885 ,  Y10S977/906

摘要： The present invention is related to the field of medicine, particularly to the use of new adjuvant formulations with vaccine antigens. The technical objective pursued with this invention is, precisely, the development of formulations that are able to increase and/or modulate the immune response of the organism to vaccine antigens in the serum and the mucous lining. With this aim, a formulation was developed that contained as the main components the surface antigen of the hepatitis B virus and the acemannan in adequate proportions. As an extension of this result, formulations were developed in which a) HBsAg was used as the homologous or heterologous antigen carrier b) delivery systems of particulated antigens and c) soluble antigens, combined with the acemannan in specific proportions. The formulations of this invention are applicable in the pharmaceutical industry as vaccine formulations for human and veterinary use.

摘要翻译： 本发明涉及药物领域，特别是涉及使用具有疫苗抗原的新辅助制剂。 本发明追求的技术目标正是开发能够增加和/或调节生物体对血清和粘液衬里中的疫苗抗原的免疫应答的制剂。 为此，开发了一种配方，其中包含乙肝病毒的表面抗原和乙酰甘露聚糖的主要成分。 作为该结果的延伸，开发了其中a）将HBsAg用作同源或异源抗原载体b）颗粒抗原的递送系统和c）可溶性抗原与特定比例的acemannan结合的制剂。 本发明的制剂可用于制药工业，作为用于人类和兽医用途的疫苗制剂。

公开(公告)号：US20090104223A1

公开(公告)日：2009-04-23

申请号：US11870088

申请日：2007-10-10

申请人： Julio Cesar Aguilar Rubido ,  Eduardo Penton Arias ,  Dina Tleugabulova ,  Minerva Sewer Mensies ,  Verena Lucila Muzio Gonzalez ,  Gerardo Enrique Guillen Nieto ,  Iloki Assanga Simon Bernard ,  Luis Javier Cruz Ricondo ,  Viviana Falcon Cama ,  Yanet Tambara Hernandez

发明人： Julio Cesar Aguilar Rubido ,  Eduardo Penton Arias ,  Dina Tleugabulova ,  Minerva Sewer Mensies ,  Verena Lucila Muzio Gonzalez ,  Gerardo Enrique Guillen Nieto ,  Iloki Assanga Simon Bernard ,  Luis Javier Cruz Ricondo ,  Viviana Falcon Cama ,  Yanet Tambara Hernandez

IPC分类号： A61K39/385 ,  A61P37/04

CPC分类号： A61K39/292 ,  A61K39/12 ,  A61K2039/54 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/575 ,  C12N2730/10134

摘要： The invention relates to a method for obtaining aggregated antigenic structures that are capable of enhancing an immune response to aggregate antigens administered systemically and/or mucosally generating powerful immune response and to the chemical structures resulting from the application of said method, to the formulations obtained from such structures and their use. The method describes the obtention of novel aggregate antigenic structures by using aggregating, delipidating or oxidating agents or compounds enabling the release of lipids from the particles and their heterogeneous aggregation, wherein aggregates with particle sizes of between 30 and 500 nm are subsequently selected by means of a molecular exclusion process. The aggregation state can also be provoket inside the yeast by changing incubation conditions. The resulting structures can be used conveniently adjuvated or in a formulation in which several antigens can be introduced, wherein synergism between said components is found with respect to the immunogenicity of the response obtained. The preparation may also contain stabilizers and preservatives. The resulting antigenic structures can be used in the pharmaceutical industry as preventive or therapeutic vaccine formulation both for human and veterinary use and as part of diagnostic system.

摘要翻译： 本发明涉及一种用于获得聚集的抗原结构的方法，所述聚集的抗原结构能够增强对于全身施用和/或粘膜产生强大的免疫应答的聚集抗体的免疫应答和由应用所述方法产生的化学结构与从 这种结构及其用途。 该方法描述了通过使用聚集，脱脂或氧化剂或能够从颗粒中释放脂质及其不均匀聚集的新型聚集抗原结构的获得，其中随后通过以下步骤选择粒度为30-500nm的聚集体： 分子排除过程。 聚集状态也可以通过改变孵育条件在酵母内进行。 所得到的结构可以方便地用于佐剂或在可以引入几种抗原的制剂中，其中发现所述组分之间的协同作用与获得的反应的免疫原性有关。 该制剂还可含有稳定剂和防腐剂。 所得到的抗原结构可用于制药工业，作为用于人类和兽医用途的预防或治疗疫苗制剂，并且作为诊断系统的一部分。

公开(公告)号：US09518085B2

公开(公告)日：2016-12-13

申请号：US14127369

申请日：2012-06-29

申请人： Giselle Penton Rol ,  Alexey Llopiz Arzuaga ,  Javier Marin Prida ,  Eduardo Penton Arias ,  Efrain Rodriguez Jimenez ,  Alexis Musacchio Lasa ,  Vladimir Armando Besada Perez ,  Gilberto Lazaro Pardo Andreu ,  Luis Javier Gonzalez Lopez ,  Nancy Pavon Fuentes ,  Gerardo Enrique Guillen Nieto ,  Pedro Antonio Lopez Saura

发明人： Giselle Penton Rol ,  Alexey Llopiz Arzuaga ,  Javier Marin Prida ,  Eduardo Penton Arias ,  Efrain Rodriguez Jimenez ,  Alexis Musacchio Lasa ,  Vladimir Armando Besada Perez ,  Gilberto Lazaro Pardo Andreu ,  Luis Javier Gonzalez Lopez ,  Nancy Pavon Fuentes ,  Gerardo Enrique Guillen Nieto ,  Pedro Antonio Lopez Saura

IPC分类号： C07K7/06 ,  C07K5/08 ,  A61K38/00 ,  C07K5/10 ,  C07K5/083 ,  C07K5/103 ,  A61K38/06 ,  A61K38/07 ,  A61K38/18 ,  A61K38/20 ,  A61K38/21 ,  A61K38/25 ,  A61K38/08

CPC分类号： A61K31/409 ,  A61K38/00 ,  A61K38/06 ,  A61K38/07 ,  A61K38/08 ,  A61K38/1816 ,  A61K38/2013 ,  A61K38/21 ,  A61K38/212 ,  A61K38/215 ,  A61K38/25 ,  A61K47/55 ,  C07K5/08 ,  C07K5/081 ,  C07K5/10 ,  C07K5/1008 ,  C07K7/06 ,  A61K2300/00 ,  A61K36/06

摘要： The present invention describes peptides comprising phycocyanobilin (PCB), as well as the medical use of said peptides and that of PCB, due to the neuroprotector and/or neuroregenerative effects identified for them. Furthermore, pharmaceutical combinations of said peptides and of PCB with proteins or other peptides with synergic effect justify their use for ischemic or neurodegenerative CNS disease treatment.

摘要翻译： 本发明描述了由于对其鉴定的神经保护剂和/或神经再生作用，包含珊瑚蓝菌素（PCB）的肽以及所述肽和PCB的医学用途。 此外，所述肽和PCB与具有协同作用的蛋白质或其他肽的药物组合证明其用于缺血性或神经退行性CNS疾病治疗。

公开(公告)号：US20090280087A1

公开(公告)日：2009-11-12

申请号：US12091776

申请日：2006-10-30

申请人： Giselle Penton Rol ,  Majel Cervantes Llanos ,  Eduardo Penton Arias ,  Diana Garcia del Barco Herrera ,  Carmen Maria Valenzuela Silva ,  Pedro Antonio Lopez Saura ,  Gerardo Enrique Guillen Nieto

发明人： Giselle Penton Rol ,  Majel Cervantes Llanos ,  Eduardo Penton Arias ,  Diana Garcia del Barco Herrera ,  Carmen Maria Valenzuela Silva ,  Pedro Antonio Lopez Saura ,  Gerardo Enrique Guillen Nieto

IPC分类号： A61K38/21 ,  A61K38/16 ,  A61P35/00 ,  A61P11/00 ,  A61P37/00 ,  A61P19/02

CPC分类号： A61K31/40 ,  A61K38/212 ,  A61K2300/00

摘要： The present invention consists of the combination of Interferon alpha and C-Phycocyanin (IFN-α/C-Phyco) for obtaining a pharmaceutical preparation for autoimmune disease, allergy and cancer treatments. The anti-inflammatory, immunomodulator, antioxidant, anti-viral, anti-proliferative and anti-tumoral effects, associated to the regulatory T cell inducer effect demonstrated in this invention is the rationale for the use of the IFN-α/C-Phyco combination in these diseases.

摘要翻译： 本发明由干扰素α和C-藻蓝蛋白（IFN-α/ C-Phyco）的组合组成，用于获得用于自身免疫疾病，过敏和癌症治疗的药物制剂。 与本发明中证明的调节性T细胞诱导物效应相关的抗炎，免疫调节剂，抗氧化剂，抗病毒，抗增殖和抗肿瘤作用是使用IFN-α/ C-Phyco组合的理由 在这些疾病中。

公开(公告)号：US08110182B2

公开(公告)日：2012-02-07

申请号：US12091776

申请日：2006-10-30

申请人： Giselle Penton Rol ,  Majel Cervantes Llanos ,  Eduardo Penton Arias ,  Diana Garcia del Barco Herrera ,  Carmen Maria Valenzuela Silva ,  Pedro Antonio Lopez Saura ,  Gerardo Enrique Guillen Nieto

发明人： Giselle Penton Rol ,  Majel Cervantes Llanos ,  Eduardo Penton Arias ,  Diana Garcia del Barco Herrera ,  Carmen Maria Valenzuela Silva ,  Pedro Antonio Lopez Saura ,  Gerardo Enrique Guillen Nieto

IPC分类号： A61K38/20 ,  A61K31/33 ,  C07K14/56 ,  C07K14/41

CPC分类号： A61K31/40 ,  A61K38/212 ,  A61K2300/00

摘要： The present invention consists of the combination of Interferon alpha and C-Phycocyanin (IFN-α/C-Phyco) for obtaining a pharmaceutical preparation for autoimmune disease, allergy and cancer treatments. The anti-inflammatory, immunomodulator, antioxidant, anti-viral, anti-proliferative and anti-tumoral effects, associated to the regulatory T cell inducer effect demonstrated in this invention is the rationale for the use of the IFN-α/C-Phyco combination in these diseases.

摘要翻译： 本发明由干扰素α和C-藻蓝蛋白（IFN-α/ C-Phyco）的组合组成，用于获得用于自身免疫疾病，过敏和癌症治疗的药物制剂。 与本发明中证明的调节性T细胞诱导物效应相关的抗炎，免疫调节剂，抗氧化剂，抗病毒，抗增殖和抗肿瘤作用是使用IFN-α/ C-Phyco组合的理由 在这些疾病中。